Health Canada has approved the use of Sunovion Pharmaceuticals’ Aptiom (eslicarbazepine acetate) as monotherapy for partial-onset seizures in adults with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy. Aptiom is now indicated in Canada as monotherapy and as adjunctive therapy for the treatment of partial-onset seizures (POS)…